サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1097182

米国の調剤薬局市場 (2022-2030年)：市場規模 (薬局タイプ・滅菌区分・製品・用途・調剤タイプ・治療領域別)・成長の潜在性・価格動向・市場シェア・予測

U.S. Compounding Pharmacies Market Size By Pharmacy Type, By Sterility, By Product, By Application, By Compounding Type, By Therapeutic Area, Industry Analysis Report, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030
出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 101 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
米国の調剤薬局市場 (2022-2030年)：市場規模 (薬局タイプ・滅菌区分・製品・用途・調剤タイプ・治療領域別)・成長の潜在性・価格動向・市場シェア・予測
出版日: 2022年06月30日
発行: Global Market Insights Inc.
ページ情報: 英文 101 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の調剤薬局の市場は、個別化医療の受け入れの拡大により、2030年にかけて力強い成長を示すと予測されています。

また、米国では医薬品不足が深刻化していること、調剤薬の入手が容易なことも、予測期間中の市場拡大に拍車をかけると見られています。

用途別で見ると、動物病院による調剤薬の採用率が上昇していることから、獣医の部門が予測期間中に5.1%を超えるCAGRを示すと予測されています。また、製品別では、経鼻調剤薬で容易に治療できる耳鼻咽喉科疾患の増加から、経鼻薬の部門が予測期間中に約5.5%のCAGRで成長すると予測されています。

当レポートでは、米国の調剤薬局の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制・償還環境、市場規模の推移・予測、各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 米国の調剤薬局産業の考察

  • 産業の分類
  • 産業情勢
  • 産業への影響要因
    • 促進要因
    • 潜在的リスク＆課題
  • 成長の可能性の分析
  • COVID-19：影響分析
  • 規制状況
  • 償還の情勢
  • ポーターの分析
  • 競合情勢
  • PESTEL分析

第4章 米国の調剤薬局市場：薬局タイプ別

  • 主要動向
  • 503A
  • 503B

第5章 米国の調剤薬局市場：滅菌区分別

  • 主要動向
  • 滅菌
  • 非滅菌

第6章 米国の調剤薬局市場：製品別

  • 主要動向
  • 経口剤
    • 固形剤
    • 液剤
    • 局所剤
    • 直腸薬
    • 非経口薬
    • 経鼻薬
    • 点眼薬
    • 点耳薬

第7章 米国の調剤薬局市場：用途別

  • 主要動向
  • 小児
  • 成人
  • 高齢者
  • 獣医

第8章 米国の調剤薬局市場：調剤タイプ別

  • 主要動向
  • PIA (Pharmaceutical Ingredient Alteration)
  • CUPM (Currently Unavailable Pharmaceutical Manufacturing)
  • PDA (Pharmaceutical Dosage Alteration)
  • その他

第9章 米国の調剤薬局市場：治療領域別

  • 主要動向
  • ホルモン補充療法
  • 疼痛管理
  • 皮膚科
  • 特殊医薬品
  • 栄養補助食品
  • その他

第10章 企業プロファイル

  • 戦略ダッシュボード
  • Athenex Pharma Solutions(Athenex Inc.)
  • B Braun Melsungen AG
  • Clinigen Group PLC
  • Dougherty's Pharmacy, Inc.
  • Fagron
  • Fresenius Kabi
  • ImprimisRx(Harrow Health, Inc.)
  • Institutional Pharmacy Solutions
  • ITC Compounding Pharmacy
  • Lorraine's Pharmacy
  • McGuff Company Inc(McGuff Compounding Pharmacy Services)
  • Nephron Pharmaceuticals Corporation
  • Pencol Compounding Pharmacy
  • QuVa Pharma
  • Rx3 Compounding Pharmacy
  • Triangle Compounding Pharmacies
  • Wedgewood Village Pharmacy, Inc.
図表

Data Tables

  • TABLE 1 U.S. Compounding Pharmacies market, 2017 - 2021 (USD Million)
  • TABLE 2 U.S. Compounding Pharmacies market, 2022 - 2030 (USD Million)
  • TABLE 3 Industry impact forces
  • TABLE 4 U.S. compounding pharmacies market size, by pharmacy type, 2017 - 2021 (USD Million)
  • TABLE 5 U.S. compounding pharmacies market size, by pharmacy type, 2022 - 2030 (USD Million)
  • TABLE 6 U.S. compounding pharmacies market size market, by sterility, 2017 - 2021 (USD Million)
  • TABLE 7 U.S. compounding pharmacies market size, by sterility, 2022 - 2030 (USD Million)
  • TABLE 8 U.S. compounding pharmacies market size, by product, 2017 - 2021 (USD Million)
  • TABLE 9 U.S. compounding pharmacies market size, by product, 2022 - 2030 (USD Million)
  • TABLE 10 U.S. compounding pharmacies market size, by oral, 2017 - 2021 (USD Million)
  • TABLE 11 U.S. compounding pharmacies market size, by oral, 2022 - 2030 (USD Million)
  • TABLE 12 U.S. compounding pharmacies market size, by solid preparation, 2017 - 2021 (USD Million)
  • TABLE 13 U.S. compounding pharmacies market size, by solid preparation, 2022 - 2030 (USD Million)
  • TABLE 14 U.S. compounding pharmacies market size, by liquid preparation, 2017 - 2021 (USD Million)
  • TABLE 15 U.S. compounding pharmacies market size, by liquid preparation, 2022 - 2030 (USD Million)
  • TABLE 16 U.S. compounding pharmacies market size, by topical, 2017 - 2021 (USD Million)
  • TABLE 17 U.S. compounding pharmacies market size, by topical, 2022 - 2030 (USD Million)
  • TABLE 18 U.S. compounding pharmacies market size, by rectal, 2017 - 2021 (USD Million)
  • TABLE 19 U.S. compounding pharmacies market size, by rectal, 2022 - 2030 (USD Million)
  • TABLE 20 U.S. compounding pharmacies market size, by parenteral, 2017 - 2021 (USD Million)
  • TABLE 21 U.S. compounding pharmacies market size, by parenteral, 2022 - 2030 (USD Million)
  • TABLE 22 U.S. compounding pharmacies market size, by application, 2017 - 2021 (USD Million)
  • TABLE 23 U.S. compounding pharmacies market size, by application, 2022 - 2030 (USD Million)
  • TABLE 24 U.S. compounding pharmacies market size, by compounding type, 2017 - 2021 (USD Million)
  • TABLE 25 U.S. compounding pharmacies market size, by compounding type, 2022 - 2030 (USD Million)
  • TABLE 26 U.S. compounding pharmacies market size, by therapeutic area, 2017 - 2021 (USD Million)
  • TABLE 27 U.S. compounding pharmacies market size, by therapeutic area, 2022 - 2030 (USD Million)

Charts & Figures

  • FIG. 1 Top-down approach
  • FIG. 2 Top-down approach
  • FIG. 3 Breakdown of primary participants
  • FIG. 4 U.S. compounding pharmacies industry 360 degree synopsis, 2017 - 2030
  • FIG. 5 Industry segmentation
  • FIG. 6 Industry landscape, 2017-2030 (USD Million)
  • FIG. 7 Growth potential analysis, by pharmacy type
  • FIG. 8 Growth potential analysis, by sterility
  • FIG. 9 Growth potential analysis, product
  • FIG. 10 Growth potential analysis, by application
  • FIG. 11 Growth potential analysis, by compounding type
  • FIG. 12 Growth potential analysis, by therapeutic area
  • FIG. 13 Porter's analysis
  • FIG. 14 PESTEL analysis
  • FIG. 15 Key segment trends, by pharmacy type, 2021
  • FIG. 16 Key segment trends, by sterility, 2021
  • FIG. 17 Key segment trends, by product, 2021
  • FIG. 18 Key segment trends, by application, 2021
  • FIG. 19 Key segment trends, by compounding type, 2021
  • FIG. 20 Key segment trends, by therapeutic area, 2021
  • FIG. 21 Strategy dashboard, 2021
目次
Product Code: 2961

The U.S. compounding pharmacies market is set to witness robust growth through 2030 owing to increasing acceptance of personalized medicines. In addition, easy availability of compounded drugs, along with prevalent drug shortage in the U.S., is also expected to spur market expansion over the forecast timeframe.

Notably, industry players have been adopting profitable strategies to improve their business presence, enhancing overall market dynamics. For instance, in March 2022, Medisca, a supplier of pharmaceutical equipment and ingredients, inked an agreement with SUANFARMA, a European distributor and manufacturer of pharmaceutical ingredients, for the global distribution and supply of Thyroid Powder, USP, for which it leveraged its partnership with Deebio, a pharmaceutical manufacturer.

The U.S. compounding pharmacies market has been bifurcated in terms of application, product, pharmacy type, sterility, compounding type, and therapeutic area. Based on application, the market has been segmented into adult, veterinary, geriatric, and pediatric. Owing to rising adoption rates of compounded medication by veterinary clinics, the veterinary sub-segment is set to depict a CAGR of more than 5.1% between 2022 and 2030.

On the basis of product, the U.S. compounding pharmacies market has been divided into topical, parenteral, nasal, otic, ophthalmic, rectal, and oral. The nasal sub-segment is foreseen to expand at a CAGR of about 5.5% over the forecast timeframe driven by increasing occurrences of ENT disorders that can be treated easily with nasal compounded medications. Additionally, the ease of usage of compounded nasal drops is likely to aid segmental growth.

With respect to pharmacy type, the market has been branched into 503A and 503B. The 503B sub-segment garnered a market share of over 56.5% in 2021 owing to a surge in drug shortages in the U.S., coupled with mounting preference for outsourcing facilities for manufacturing drugs that are in short supply.

By sterility, the U.S. compounding pharmacies market has been fragmented into non-sterile and sterile. In 2021, the non-sterile sub-segment was valued at more than $3.7 billion due to several benefits of non-sterile compounded medications, such as easy availability, self-administration, and personalized route of administration.

With regards to compounding type, the market has been segregated into unavailable pharmaceutical manufacturing (CUPM), pharmaceutical ingredient alteration (PIA), currently pharmaceutical dosage alteration (PDA), and others. The currently unavailable pharmaceutical manufacturing (CUPM) sub-segment held a market share of about 22.8% in 2021 on account of surging incidences of drug shortage across the U.S. In addition, compounded pharmacies play a vital role in curbing drug shortages, which is primed to supplement segmental development.

From the perspective of therapeutic area, the U.S. compounding pharmacies market has been categorized into nutritional supplements, dermatology, hormone replacement, pain management, specialty drugs, and others. In 2021, the specialty drugs sub-segment held around 9.6% market share supported by the ease of formulation of specialty drugs by compounding pharmacies, coupled with rising interest in personalized medicine to predict, diagnose, and treat diseases.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 U.S. compounding pharmacies industry 360 degree synopsis, 2017 - 2030

Chapter 3 US Compounding Pharmacies Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2030 (USD Million)
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increasing geriatric population and improved longevity
      • 3.3.1.2 Growing acceptance of personalized medicines in U.S.
      • 3.3.1.3 Increasing drug shortage in the country
      • 3.3.1.4 Convenience of using compounded drugs
      • 3.3.1.5 Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women
    • 3.3.2 Restraints
      • 3.3.2.1 Issues related to safety standards of compounded drugs
      • 3.3.2.2 Changing regulatory scenario
  • 3.4 Growth potential analysis
    • 3.4.1 By pharmacy type
    • 3.4.2 By sterility
    • 3.4.3 By product
    • 3.4.4 By application
    • 3.4.5 By compounding type
    • 3.4.6 By therapeutic area
  • 3.5 COVID-19 impact analysis
  • 3.6 Regulatory landscape
  • 3.7 Reimbursement landscape
  • 3.8 Porter's analysis
  • 3.9 Competitive landscape, 2021
  • 3.10 PESTEL analysis

Chapter 4 US Compounding Pharmacies Market, By Pharmacy Type

  • 4.1 Key segment trends
  • 4.2 503A
    • 4.2.1 Market size, by 503A, 2017-2030 (USD Million)
  • 4.3 503B
    • 4.3.1 Market size, by 503B, 2017-2030 (USD Million)

Chapter 5 US Compounding Pharmacies Market, By Sterility

  • 5.1 Key segment trends
  • 5.2 Sterile
    • 5.2.1 Market size, by sterile, 2017-2030 (USD Million)
  • 5.3 Non-sterile
    • 5.3.1 Market size, by non-sterile, 2017-2030 (USD Million)

Chapter 6 US Compounding Pharmacies Market, By Product

  • 6.1 Key segment trends
  • 6.2 Oral
    • 6.2.1 Market size, by oral, 2017-2030 (USD Million)
    • 6.2.2 Solid preparation
      • 6.2.2.1 Market size, by solid preparation, 2017-2030 (USD Million)
      • 6.2.2.2 Tablets
        • 6.2.2.2.1 Market size, by tablets, 2017 - 2030 (USD Million)
      • 6.2.2.3 Capsules
        • 6.2.2.3.1 Market size, by capsules, 2017 - 2030 (USD Million)
      • 6.2.2.4 Granules
        • 6.2.2.4.1 Market size, by granules, 2017 - 2030 (USD Million)
      • 6.2.2.5 Powder
        • 6.2.2.5.1 Market size, by powder, 2017 - 2030 (USD Million)
      • 6.2.2.6 Others
        • 6.2.2.6.1 Market size, by others, 2017 - 2030 (USD Million)
    • 6.2.3 Liquid preparation
      • 6.2.3.1 Market size, by liquid preparation, 2017-2030 (USD Million)
      • 6.2.3.2 Solutions
        • 6.2.3.2.1 Market size, by solutions, 2017 - 2030 (USD Million)
      • 6.2.3.3 Suspension
        • 6.2.3.3.1 Market size, by suspension, 2017 - 2030 (USD Million)
      • 6.2.3.4 Emulsion
        • 6.2.3.4.1 Market size, by emulsion, 2017 - 2030 (USD Million)
      • 6.2.3.5 Syrup
        • 6.2.3.5.1 Market size, by syrup, 2017 - 2030 (USD Million)
      • 6.2.3.6 Others
        • 6.2.3.6.1 Market size, by others, 2017 - 2030 (USD Million)
    • 6.2.4 Topical
      • 6.2.4.1 Market size, by topical, 2017-2030 (USD Million)
      • 6.2.4.2 Creams
        • 6.2.4.2.1 Market size, by creams, 2017 - 2030 (USD Million)
      • 6.2.4.3 Gels
        • 6.2.4.3.1 Market size, by gels, 2017 - 2030 (USD Million)
      • 6.2.4.4 Pastes
        • 6.2.4.4.1 Market size, by pastes, 2017 - 2030 (USD Million)
      • 6.2.4.5 Ointments
        • 6.2.4.5.1 Market size, by ointments, 2017 - 2030 (USD Million)
      • 6.2.4.6 Others
        • 6.2.4.6.1 Market size, by others, 2017 - 2030 (USD Million)
    • 6.2.5 Rectal
      • 6.2.5.1 Market size, by rectal, 2017-2030 (USD Million)
      • 6.2.5.2 Suppositories
        • 6.2.5.2.1 Market size, by suppositories, 2017 - 2030 (USD Million)
      • 6.2.5.3 Enemas
        • 6.2.5.3.1 Market size, by enemas, 2017 - 2030 (USD Million)
      • 6.2.5.4 Others
        • 6.2.5.4.1 Market size, by others, 2017 - 2030 (USD Million)
    • 6.2.6 Parenteral
      • 6.2.6.1 Market size, by parenteral, 2017-2030 (USD Million)
      • 6.2.6.2 Small volume parenteral (SVP) solutions
        • 6.2.6.2.1 Market size, by small volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
      • 6.2.6.3 Large volume parenteral (LVP) solutions
        • 6.2.6.3.1 Market size, by large volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
    • 6.2.7 Nasal
      • 6.2.7.1 Market size, by nasal, 2017-2030 (USD Million)
    • 6.2.8 Ophthalmic
      • 6.2.8.1 Market size, by ophthalmic, 2017-2030 (USD Million)
    • 6.2.9 Otic
      • 6.2.9.1 Market size, by otic, 2017-2030 (USD Million)

Chapter 7 US Compounding Pharmacies Market, By Application

  • 7.1 Key segment trends
  • 7.2 Pediatric
    • 7.2.1 Market size, by pediatric, 2017-2030 (USD Million)
  • 7.3 Adult
    • 7.3.1 Market size, by adult, 2017-2030 (USD Million)
  • 7.4 Geriatric
    • 7.4.1 Market size, by geriatric, 2017-2030 (USD Million)
  • 7.5 Veterinary
    • 7.5.1 Market size, by veterinary, 2017-2030 (USD Million)

Chapter 8 US Compounding Pharmacies Market, By Compounding Type

  • 8.1 Key segment trends
  • 8.2 Pharmaceutical Ingredient Alteration (PIA)
    • 8.2.1 Market size, by pharmaceutical ingredient alteration (PIA), 2017-2030 (USD Million)
  • 8.3 Currently Unavailable Pharmaceutical Manufacturing (CUPM)
    • 8.3.1 Market size, by currently unavailable pharmaceutical manufacturing (CUPM), 2017-2030 (USD Million)
  • 8.4 Pharmaceutical Dosage Alteration (PDA)
    • 8.4.1 Market size, by pharmaceutical dosage alteration (PIA), 2017-2030 (USD Million)
  • 8.5 Others
    • 8.5.1 Market size, by others, 2017-2030 (USD Million)

Chapter 9 US Compounding Pharmacies Market, By Therapeutic Area

  • 9.1 Key segment trends
  • 9.2 Hormone replacement
    • 9.2.1 Market size, by hormone replacement, 2017-2030 (USD Million)
  • 9.3 Pain management
    • 9.3.1 Market size, by pain management, 2017-2030 (USD Million)
  • 9.4 Dermatology
    • 9.4.1 Market size, by dermatology, 2017-2030 (USD Million)
  • 9.5 Specialty drugs
    • 9.5.1 Market size, by specialty drugs, 2017-2030 (USD Million)
  • 9.6 Nutritional supplements
    • 9.6.1 Market size, by nutritional supplements, 2017-2030 (USD Million)
  • 9.7 Others
    • 9.7.1 Market size, by others, 2017-2030 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Strategy dashboard, 2021
  • 10.2 Athenex Pharma Solutions (Athenex Inc.)
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 B Braun Melsungen AG
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 SWOT analysis
  • 10.4 Clinigen Group PLC
    • 10.4.1 Business overview
    • 10.4.2 Financial data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 Dougherty's Pharmacy, Inc.
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 SWOT analysis
  • 10.6 Fagron
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 Fresenius Kabi
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 Strategic outlook
    • 10.7.5 SWOT analysis
  • 10.8 ImprimisRx (Harrow Health, Inc.)
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 Strategic outlook
    • 10.8.5 SWOT analysis
  • 10.9 Institutional Pharmacy Solutions
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 Strategic outlook
    • 10.9.5 SWOT analysis
  • 10.10 ITC Compounding Pharmacy
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 Strategic outlook
    • 10.10.5 SWOT analysis
  • 10.11 Lorraine's Pharmacy
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 Strategic outlook
    • 10.11.5 SWOT analysis
  • 10.12 McGuff Company Inc (McGuff Compounding Pharmacy Services)
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 Nephron Pharmaceuticals Corporation
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 Strategic outlook
    • 10.13.5 SWOT analysis
  • 10.14 Pencol Compounding Pharmacy
    • 10.14.1 Business overview
    • 10.14.2 Financial data
    • 10.14.3 Product landscape
    • 10.14.4 Strategic outlook
    • 10.14.5 SWOT analysis
  • 10.15 QuVa Pharma
    • 10.15.1 Business overview
    • 10.15.2 Financial data
    • 10.15.3 Product landscape
    • 10.15.4 Strategic outlook
    • 10.15.5 SWOT analysis
  • 10.16 Rx3 Compounding Pharmacy
    • 10.16.1 Business overview
    • 10.16.2 Financial data
    • 10.16.3 Product landscape
    • 10.16.4 Strategic outlook
    • 10.16.5 SWOT analysis
  • 10.17 Triangle Compounding Pharmacies
    • 10.17.1 Business overview
    • 10.17.2 Financial data
    • 10.17.3 Product landscape
    • 10.17.4 Strategic outlook
    • 10.17.5 SWOT analysis
  • 10.18 Wedgewood Village Pharmacy, Inc.
    • 10.18.1 Business overview
    • 10.18.2 Financial data
    • 10.18.3 Product landscape
    • 10.18.4 Strategic outlook
    • 10.18.5 SWOT analysis